Down syndrome screening tests, offered during the first or second trimester, estimate the likelihood…
#firsttrimester #ntscan #doublemarker
Down syndrome screening tests, offered during the first or second trimester, estimate the likelihood of a fetus having trisomy 21, 18, or 13. Common methods include Non-Invasive Prenatal Testing (NIPT/cfDNA) after 10 weeks (>99% accuracy) or a combined test (ultrasound + blood test) at 11–14 weeks. These tests are non-invasive and pose no risk of miscarriage.
Key Screening Methods
Non-Invasive Prenatal Testing (NIPT/cfDNA): Analyzes fetal DNA in the mother’s blood (after 10 weeks).
First Trimester Combined Test: Measures PAPP-A/hCG in blood and Nuchal Translucency (NT) via ultrasound (11-14 weeks).
Quadruple (Quad) Test: Second trimester blood test (14–20 weeks) measuring four substances: AFP, hCG, uE3, and Inhibin A.
Understanding Results
Screening tests only indicate risk (high vs. low) and do not provide a definitive diagnosis, as noted in this article from the NIH.
Diagnostic tests (CVS or Amniocentesis) are more invasive but provide a definitive diagnosis.
Common Procedures
Nuchal Translucency (NT) Scan: A specialized 11-14 week ultrasound measuring fluid behind the baby’s neck.
Amniocentesis: A second-trimester diagnostic test that checks chromosomes from amniotic fluid.
Chorionic Villus Sampling (CVS): A first-trimester diagnostic test that takes a placenta sample. #firsttrimester #ntscan #doublemarker #downssyndromescreening #fts
Comments
Comments from the original post on Instagram
No comments yet
